Pascal Biosciences
  • Home
  • About Us
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact
Skip to content

28Nov 2018

Pascal Biosciences Expands Leadership Team to Support Strategic Advancement of Its Cannabinoid Based Programs

  • Nov 28, 2018
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, November 28, 2018 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the strengthening of its leadership team with the appointments of seasoned executives in therapeutic…

Read More

10Nov 2018

Pascal Biosciences CEO interview on Canada Pot Talks 107.7 Pulse FM (minute 46)

  • Nov 10, 2018
  • In the News

Listen to an interview with CEO Patrick Gray on Canada Pot Talks. Canada Pot Talks - November 10th 2018

Read More

8Nov 2018

CFN's exclusive Interview with Pascal Biosciences

  • Nov 8, 2018
  • In the News

CEO Patrick Gray sat down with CFN Media for an exclusive interview. Read the full interview here.  

Read More

5Nov 2018

Pascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells

  • Nov 5, 2018
  • Press Releases

VANCOUVER, British Columbia and SEATTLE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today announced the peer reviewed publication and upcoming presentation of their recently licensed cannabinoid-derived drug program for…

Read More

Recent Posts

  • Pascal Biosciences Signs Term Sheet for Acquisition of THC Essentials
  • PASCAL BIOSCIENCES PLANS NEW DIRECTION TO INCLUDE CONTRACT RESEARCH
  • Pascal Biosciences First To File Patent For COVID-19 Antiviral Activity With CBD
  • Pascal Biosciences Sign Term Sheet for $2,000,000 Convertible Notes
  • Pascal Biosciences Settles Certain Outstanding Payables with Issuance of Shares and Details Share-related Compensation to Employees

Categories

  • In the News
  • Press Releases
  • Uncategorized

Archives

  • December 2022
  • June 2022
  • April 2022
  • March 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • June 2021
  • March 2021
  • January 2021
  • December 2020
  • November 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • March 2020
  • October 2019
  • September 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • July 2018
  • June 2018
  • February 2018
  • December 2017
  • September 2017
  • May 2017
  • March 2017
  • November 2016
  • October 2016
  • September 2016

About

Pascal Biosciences Inc. (TSX-V: PAS, FSE:6PB.F, OTC:PSCBF) is a biotechnology company focused on developing cannabinoid-based and targeted therapeutics to fight cancer.

Locations

USA

Fluke Hall, Suite 304
Box 352141
4000 Mason Road
Seattle, WA 98195-2141

Canada

280 7th Avenue East
Vancouver, BC V5T 0B4

Contact

Phone

206.221.3443

Email

info@pascalbiosciences.com

Investors

invest@pascalbiosciences.com

Partnering & Business Development

bd@pascalbiosciences.com

Let's Connect

  • Facebook
  • Twitter
  • Linked
  • Home
  • Company
  • Programs
  • News
  • Investors
  • Contact
  • Disclaimer
  • Legal Notices

© Copyright 2023 Pascal Biosciences Inc. All rights reserved.   Seattle Website Design by Jordan Crown Design

  • Home
  • About Us
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact

‹ › ×